Paradoxical LTP maintenance with inhibition of protein synthesis and the proteasome suggests a novel protein synthesis requirement for early LTP reversal
Paul Smolen, Douglas A. Baxter, John H. Byrne

TL;DR
This study presents a computational model explaining the paradoxical maintenance of late long-term potentiation (L-LTP) despite inhibition of protein synthesis and degradation, highlighting a novel protein synthesis requirement for early LTP reversal.
Contribution
The paper introduces a differential equation model of LTP that accounts for the paradoxical preservation of L-LTP under combined inhibition of synthesis and degradation, proposing new molecular mechanisms.
Findings
Model reproduces empirical LTP behaviors
Predicts a novel synaptic state ED before L-LTP
Identifies a time window for UPS activity
Abstract
The transition from early long-term potentiation (E-LTP) to late LTP (L-LTP) involves protein synthesis and degradation. L-LTP is blocked by inhibiting either protein synthesis or proteasome-dependent degradation prior to and during a tetanic stimulus, but paradoxically, L-LTP is not blocked when synthesis and degradation are inhibited simultaneously, suggesting counter-acting positive and negative proteins regulate L-LTP. To investigate this paradox, we modeled LTP at the Schaffer collateral synapse. Nine differential equations describe the levels of positive and negative regulator proteins (PP and NP) and transitions among five discrete synaptic states, a basal state (BAS), three E-LTP states (EP1, EP2, ED), and a L-LTP state (LP). A stimulus initiates the transition from BAS to EP1 and from EP1 to EP2, initiates the synthesis of PP and NP, and activates the ubiquitin-proteasome…
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsNeuroscience and Neuropharmacology Research · Alzheimer's disease research and treatments · Amino Acid Enzymes and Metabolism
